Up to 15% of older adults may be routinely taking aspirin for primary prevention, and most of them understand the excess ...

Baxdrostat meets primary and all secondary endpoints in BaxHTN phase III trial in patients with uncontrolled or treatment resistant hypertension: Cambridge, UK Wednesday, July 16, ...

Researchers determined a short duration of anticoagulation therapy could be beneficial in comparison to a longer course for primary treatment VTE.

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

AstraZeneca announced that baxdrostat, a selective aldosterone synthase inhibitor, met its primary and all secondary ...

The findings from a contemporary US cohort point to the need for better ways to identify and treat those who are at risk.

Johnson & Johnson submits sNDA to US FDA for Caplyta for prevention of relapse in schizophrenia: Titusville, New Jersey Wednesday, July 9, 2025, 14:00 Hrs [IST] Johnson & Johnson ...

Threshold for permanent impairment: The Bill proposes a higher threshold for psychological injuries, requiring a degree of ...

Titusville: Johnson & Johnson has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug ...

The phase 3 BaxHTN trial has been evaluating two doses of the drug in patients with uncontrolled hypertension being treated ...

At two doses, baxdrostat demonstrated significant reduction in mean seated systolic BP vs. placebo at 12 weeks among patients ...

The Matthew J. Morahan III Health Assessment Center for Athletes has provided over 50,000 concussion and cardiac screenings ...